CA
ACAD icon

Crewe Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Crewe Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-150
Closed -$2.82K – 871
2023
Q1 		$2.82K Sell
150
-89
-37% -$1.7K ﹤0.01% 696
2022
Q4 		$3.81K Sell
239
-158
-40% -$2.47K ﹤0.01% 728
2022
Q3 		$6K Hold
397
– – ﹤0.01% 785
2022
Q2 		$6K Buy
+397
New +$7.41K ﹤0.01% 705

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Crewe Advisors's ACAD Position: Q2 2023 in Review

Crewe Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2023, closing a stake of 150 shares — an estimated $2.82K sold.

Crewe Advisors first reported a position in ACAD in Q2 2022 and held it in 4 quarters. The position peaked at $6K in Q3 2022. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

  • Crewe Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Crewe Advisors sold 150 Acadia Pharmaceuticals shares in Q2 2023, an estimated $2.82K.
  • Crewe Advisors first reported a position in Acadia Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • Crewe Advisors's Acadia Pharmaceuticals position peaked at $6K in Q3 2022.
  • 236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.